Mesa Biotech: Mesa Biotech to Receive up to $15.4 Million Funding from the National Institutes of Health for Accelerated Scale-up and Deployment

Mesa Biotech, developers of an affordable, easy to use, handheld testing platform for infectious diseases diagnosis, today announced it has been awarded a contract up to $15.4 million from the National Institutes of Health's (NIH) Rapid Acceleration of Diagnostics (RADx) program for its Accula SARS-CoV-2 Test, which gives COVID-19 diagnostic results in 30 minutes at the point of care (POC)